ascopubs.org

Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in cancer patients with anemia receiving cyclic chemotherapy

Early results from a novel treatment strategy for chemotherapy-related anemia: Epoetin alfa 60,000 U SC QW induction followed by 60,000 U SC Q2W Conclusions: Epoetin alfa was safe and well tolerated ...
The American Journal of Managed Care

COMMANDS: Updated Data for Luspatercept for Treatment of Anemia in ESA-Naïve Patients With Lower-Risk MDS Presented at ASH

The data were presented December 9, 2023, during the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California. Updated results from the primary analysis of the phase ...
ascopubs.org

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188) Eligible patients were randomly ...
Medscape

Luspatercept May Prolong Life in Low-Risk MDS

A new analysis from the COMMANDS trial of erythroid maturation agent luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) shows not only sustained, longer-term benefits over ...
The American Journal of Managed Care

COMMANDS: Luspatercept Boosts Population With Lower-Risk Myelodysplastic Syndromes Who Are Freed From Blood Transfusions

The study's lead author said patients would experience improved quality of life due to fewer transfusions and fewer trips to the clinic to receive treatment. More patients at risk of anemia from lower ...